BR112017017529A2 - derivado de ácido quenodeoxicólico deuterado e composição farmacêutica que compreende composto do mesmo - Google Patents

derivado de ácido quenodeoxicólico deuterado e composição farmacêutica que compreende composto do mesmo

Info

Publication number
BR112017017529A2
BR112017017529A2 BR112017017529-0A BR112017017529A BR112017017529A2 BR 112017017529 A2 BR112017017529 A2 BR 112017017529A2 BR 112017017529 A BR112017017529 A BR 112017017529A BR 112017017529 A2 BR112017017529 A2 BR 112017017529A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
chenodeoxycholic acid
derived
same
Prior art date
Application number
BR112017017529-0A
Other languages
English (en)
Chinese (zh)
Inventor
Lv Binhua
Sheng Zelin
Li Chengwei
Original Assignee
Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Zelgen Biopharmaceuticals Co., Ltd. filed Critical Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Publication of BR112017017529A2 publication Critical patent/BR112017017529A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/007—Steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

a presente invenção se refere a um derivado de ácido quenodeoxicólico deuterado e composição farmacêutica que compreende o composto da mesma. especificamente, são revelados um derivado de ácido quenodeoxicólico deuterado representado pela fórmula (i) e uma composição farmacêutica que compreende o composto ou polimorfo da mesma, sais farmaceuticamente aceitáveis, hidratos ou solvatos. o composto acima da presente invenção é usado para tratar e/ou prevenir esteato-hepatite não alcoólica, doença hepática gordurosa não alcoólicas, cálculos biliares, cirrose biliar primária, cirrose, etc.
BR112017017529-0A 2015-02-16 2016-02-16 derivado de ácido quenodeoxicólico deuterado e composição farmacêutica que compreende composto do mesmo BR112017017529A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510084738.5A CN105985396A (zh) 2015-02-16 2015-02-16 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
CN201510084738.5 2015-02-16
PCT/CN2016/073891 WO2016131414A1 (zh) 2015-02-16 2016-02-16 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物

Publications (1)

Publication Number Publication Date
BR112017017529A2 true BR112017017529A2 (pt) 2018-04-17

Family

ID=56692502

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017017529-0A BR112017017529A2 (pt) 2015-02-16 2016-02-16 derivado de ácido quenodeoxicólico deuterado e composição farmacêutica que compreende composto do mesmo

Country Status (11)

Country Link
US (1) US10544185B2 (pt)
EP (1) EP3260463B1 (pt)
JP (1) JP6947644B2 (pt)
KR (1) KR102042112B1 (pt)
CN (2) CN105985396A (pt)
AU (1) AU2016222174B2 (pt)
BR (1) BR112017017529A2 (pt)
CA (1) CA2977109C (pt)
HK (1) HK1248712A1 (pt)
RU (1) RU2712033C2 (pt)
WO (1) WO2016131414A1 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2700264C2 (ru) 2013-04-17 2019-09-16 Сейдж Терапьютикс, Инк. 19-нор нейроактивные стероиды и способы их применения
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
KR102239541B1 (ko) 2013-04-17 2021-04-14 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
EP3868382A1 (en) 2013-07-19 2021-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
LT3488852T (lt) 2013-08-23 2021-02-25 Sage Therapeutics, Inc. Neuroaktyvūs steroidai, kompozicijos, ir jų naudojimas
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
LT3206493T (lt) 2014-10-16 2020-08-25 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti cns sutrikimams gydyti
BR112017007902B1 (pt) 2014-10-16 2023-12-05 Sage Therapeutics, Inc Composto e seu sal, composição farmacêutica e uso do referido composto e seu sal na fabricação de um medicamento para o tratamento de distúrbios do sistema nervoso central
SI3224269T1 (sl) 2014-11-27 2020-10-30 Sage Therapeutics, Inc. Sestavki in metode za zdravljenje CNS motenj
ES2857082T3 (es) 2015-01-26 2021-09-28 Sage Therapeutics Inc Composiciones y métodos para el tratamiento de trastornos del SNC
JP6875996B2 (ja) 2015-02-20 2021-05-26 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド、組成物、およびその使用
CN109467585A (zh) * 2016-03-11 2019-03-15 深圳市塔吉瑞生物医药有限公司 用于预防或治疗fxr-介导疾病的胆烷酸化合物
DK3481844T3 (da) 2016-07-11 2024-07-22 Sage Therapeutics Inc C7, C12 og C16 substituerede neuroaktive steroider og disses fremgangsmåder til anvendelse
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
KR20200031145A (ko) * 2017-07-24 2020-03-23 인터셉트 파마슈티컬즈, 인크. 동위원소 표지된 담즙산 유도체
WO2019113494A1 (en) * 2017-12-08 2019-06-13 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
AR115921A1 (es) 2018-08-10 2021-03-10 Phenex Pharmaceuticals Ag Ácido isolitocólico o ácido isoalolitocólico y derivados deuterados de los mismos para prevenir y tratar enfermedades asociadas a clostridium difficile
WO2020243488A1 (en) 2019-05-31 2020-12-03 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof
CN112142814B (zh) * 2019-06-26 2021-09-28 江苏吉贝尔药业股份有限公司 牛磺熊去氧胆酸衍生物以及包含其的药物组合物和制剂
KR20220035365A (ko) 2019-07-18 2022-03-22 엔요 파마 인터페론의 부작용을 감소시키는 방법
CN112409435B (zh) * 2019-08-23 2023-07-18 深圳云合医药科技合伙企业(有限合伙) 胆汁酸衍生物及其组合物和应用
WO2021144330A1 (en) 2020-01-15 2021-07-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of fxr agonists for treating an infection by hepatitis d virus
JP2024502673A (ja) 2021-01-14 2024-01-22 ウエヌイグレックオ・ファーマ Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強
KR102490355B1 (ko) * 2021-09-29 2023-01-26 주식회사 에이.비.아이 타우로케노디옥시콜산 함량이 증대된 담즙 추출물을 유효성분으로 포함하는 비만증 예방, 개선 또는 치료용 조성물 및 그의 제조방법
WO2024043842A1 (en) * 2022-08-22 2024-02-29 Pharmactive Ilac Sanayi Ve Ticaret A.S. Pharmaceutical compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients
WO2024144482A1 (en) * 2022-12-30 2024-07-04 Humanis Saglik Anonim Sirketi Pharmaceutical oral suspension compositions comprising chenodeoxycholic acid (cdca) as active ingredient and other relevant excipients

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU707748B2 (en) * 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6376531B1 (en) * 1998-11-13 2002-04-23 Rupert Charles Bell Method of treatment using deuterium compounds
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
IL157816A0 (en) * 2001-03-12 2004-03-28 Roberto Pellicciari Steroids as agonists for fxr
EP1568706A1 (en) * 2004-02-26 2005-08-31 Intercept Pharmaceuticals, Inc. Novel steroid agonist for FXR
WO2010054158A2 (en) * 2008-11-07 2010-05-14 Auspex Pharmaceuticals, Inc. Steroid modulators of glucocorticoid receptor
EP3150620B1 (en) 2008-11-19 2020-01-08 Intercept Pharmaceuticals, Inc. Tgr5 modulators and methods of use thereof
PT2698375T (pt) * 2008-11-19 2018-05-25 Intercept Pharmaceuticals Inc Moduladores de tgr5 e método de utilização dos mesmos
WO2013037482A1 (en) * 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
SI3336097T1 (sl) * 2012-06-19 2021-07-30 Intercept Pharmaceuticals, Inc. Priprava nekristalinične oblike obetiholne kisline
US20150112089A1 (en) * 2013-10-22 2015-04-23 Metselex, Inc. Deuterated bile acids

Also Published As

Publication number Publication date
RU2712033C2 (ru) 2020-01-24
RU2017130849A (ru) 2019-03-18
EP3260463B1 (en) 2020-09-02
CN107250149A (zh) 2017-10-13
EP3260463A1 (en) 2017-12-27
CN105985396A (zh) 2016-10-05
AU2016222174A1 (en) 2017-09-14
US10544185B2 (en) 2020-01-28
AU2016222174B2 (en) 2019-04-11
JP2018505220A (ja) 2018-02-22
KR102042112B1 (ko) 2019-11-08
CA2977109A1 (en) 2016-08-25
EP3260463A4 (en) 2018-10-31
JP6947644B2 (ja) 2021-10-13
CA2977109C (en) 2020-04-14
WO2016131414A1 (zh) 2016-08-25
CN107250149B (zh) 2020-11-24
RU2017130849A3 (pt) 2019-03-18
HK1248712A1 (zh) 2018-10-19
KR20170110723A (ko) 2017-10-11
US20180030083A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
BR112017017529A2 (pt) derivado de ácido quenodeoxicólico deuterado e composição farmacêutica que compreende composto do mesmo
CY1124404T1 (el) Παραγωγα χολικου οξεος ως αγωνιστες fxr/tgr5 και μεθοδοι χρησης αυτων
BR112018070677A2 (pt) inibidores de mcl-1 macrocíclicos para o tratamento de câncer
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112017005393A2 (pt) composto de fórmula i, método de preparação de um conjugado de fórmula a, conjugado de fórmula a1, composição compreendendo uma mistura dos compostos de conjugado de anticorpo-fármaco, composição farmacêutica, e uso de um conjugado ou de uma composição
EP4316591A3 (en) Oxysterols and methods of use thereof
BR112012019762A2 (pt) composto, composição, e, método para tratar uma doença.
AR091857A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
MX2021005052A (es) Oxiesteroles y métodos de uso de los mismos.
BR112012003578A8 (pt) Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal
BR112013018601A2 (pt) composto, uso de composto, composição farmacêutica, e, produto farmacêutico
BR112013010310A2 (pt) inibidores de acetil-coa carboxilase de lactama n1/n2
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
NZ746825A (en) Oxysterols and methods of use thereof
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
BR112012027385A2 (pt) composição para o controle de doenças de plantas e uso da mesma
BR112020016020A8 (pt) Inibidor de atr e aplicação do mesmo
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
CY1124251T1 (el) Παραγωγα καρβοξαμιδιου
CL2020001244A1 (es) Inhibidores de inmunoproteasoma.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time